28
Participants
Start Date
August 20, 2020
Primary Completion Date
August 30, 2021
Study Completion Date
May 15, 2022
APG-1252
APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
Paclitaxel
80 mg/m˄2 on days 1 and 8 of a 21-day cycle
Westmead Hospital, Westmead
Flinders Medical Centre, Bedford Park
Virginia Cancer Specialists, Fairfax
Winship Cancer Institute, Emory University, Atlanta
BRCR Medical Center, Plantation
University of Michigan Comprehensive Cancer Center, Ann Arbor
Northwestern University, Chicago
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY